董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary Sender | 男 | Independent Director | 64 | 39.64万美元 | 7.44 | 2026-05-14 |
| Antonio Gracias | 男 | Independent Director | 55 | 38.19万美元 | 57.76 | 2026-05-14 |
| Juan A. Sabater | 男 | Independent Director | 62 | 37.47万美元 | 13.86 | 2026-05-14 |
| Linda Szyper | 女 | Independent Director | 61 | 36.83万美元 | 3.66 | 2026-05-14 |
| Linda Szyper | -- | Independent Director | 60 | 未披露 | 未持股 | 2026-05-14 |
| Troy Ignelzi | -- | Independent Director | 58 | 未披露 | 未持股 | 2026-05-14 |
| Kumar Budur | 男 | Independent Director | 60 | 227.94万美元 | 18.11 | 2026-05-14 |
| Ron Philip | -- | Independent Director | 52 | 66.10万美元 | 1.96 | 2026-05-14 |
| R. Mark Graf | -- | Independent Director | 61 | 37.47万美元 | 4.27 | 2026-05-14 |
| Jeffrey M. Dayno | 男 | Chief Executive Officer,Director and President | 69 | 789.95万美元 | 40.89 | 2026-05-14 |
| Andreas Wicki | 男 | Independent Director | 67 | 未披露 | 214.79 | 2026-05-14 |
| Jeffrey S. Aronin | 男 | Chairman and Director | 58 | 7.75万美元 | 218.83 | 2026-05-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sandip Kapadia | 男 | Chief Administrative Officer and Chief Financial Officer | 55 | 320.43万美元 | 27.20 | 2026-05-14 |
| Andrew Serafin | 男 | Chief Strategy Officer | 52 | 200.93万美元 | 23.03 | 2026-05-14 |
| Peter Anastasiou | 男 | Chief Operating Officer | 55 | 37.27万美元 | 2.65 | 2026-05-14 |
| Adam Zaeske | 男 | Chief Commercial Officer | 53 | 366.42万美元 | 3.25 | 2026-05-14 |
| Kumar Budur | 男 | Chief Medical Officer | 60 | 227.94万美元 | 18.11 | 2026-05-14 |
| Jeffrey M. Dayno | 男 | Chief Executive Officer,Director and President | 69 | 789.95万美元 | 40.89 | 2026-05-14 |
董事简历
中英对照 | 中文 | 英文- Gary Sender
-
Gary Sender于2020年10月被任命为iBio, Inc.董事会成员，并于2021年12月至2022年11月10日期间担任董事会首席独立董事，当时董事会批准在任命克拉克先生为董事会主席后免去首席独立董事的职务。Sender先生目前担任审计委员会主席和薪酬委员会主席。Sender先生目前在上市公司Schrodinger, Inc.的董事会任职，并担任其审计和薪酬委员会的主席。Sender先生还在上市制药公司Harmony Biosciences Holdings, Inc.的董事会任职，并担任其审计委员会主席和薪酬委员会成员。Sender先生在上市生物技术公司Apnimed的董事会任职，是他们审计委员会的主席。Sender先生是Hula Therapeutics的董事会成员，Hula Therapeutics是一家私人控股的生物技术公司。Sender先生是一名高级管理人员和董事会成员，在大型、跨国制药和早期生物技术公司拥有超过25年的财务领导经验。2021年3月，Sender先生退休，担任Nabriva Therapeutics PLC的首席财务官，该公司是一家商业阶段的上市生物制药公司，从事治疗严重感染的创新抗感染药物的商业化和开发。他自2016年5月起担任该职位。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任协同制药公司执行副总裁兼首席财务官。在加入Synergy之前，2009年8月至2015年6月，Sender先生担任Shire plc（“Shire”）的财务高级副总裁，该公司是一家生物制药公司，自被Takeda Pharmaceutical Company Limited收购以来，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生于2004年8月至2009年7月在再生医学公司Tengion, Inc.担任首席财务官。森德先生还曾在上市制药公司默沙东公司担任多个领导职务超过15年。Sender先生获得了波士顿大学的金融学士学位和卡内基梅隆大学的工商管理硕士学位。
Gary Sender was appointed as a member of Ibio, Inc.'s Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee and as Chair of the Compensation Committee. Mr. Sender currently serves on the board of directors of Schrodinger, Inc., a publicly traded company, and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences Holdings, Inc., a publicly traded pharmaceutical company, and is the chair of their audit committee and is a member of their compensation committee. Mr. Sender serves on the board of Apnimed, a publicly traded biotechnology company, and is the chair of their audit committee. Mr. Sender serves on the board of Hula Therapeutics, a privately held biotechnology company. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi national pharmaceutical and early stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie Mellon University. - Gary Sender于2020年10月被任命为iBio, Inc.董事会成员，并于2021年12月至2022年11月10日期间担任董事会首席独立董事，当时董事会批准在任命克拉克先生为董事会主席后免去首席独立董事的职务。Sender先生目前担任审计委员会主席和薪酬委员会主席。Sender先生目前在上市公司Schrodinger, Inc.的董事会任职，并担任其审计和薪酬委员会的主席。Sender先生还在上市制药公司Harmony Biosciences Holdings, Inc.的董事会任职，并担任其审计委员会主席和薪酬委员会成员。Sender先生在上市生物技术公司Apnimed的董事会任职，是他们审计委员会的主席。Sender先生是Hula Therapeutics的董事会成员，Hula Therapeutics是一家私人控股的生物技术公司。Sender先生是一名高级管理人员和董事会成员，在大型、跨国制药和早期生物技术公司拥有超过25年的财务领导经验。2021年3月，Sender先生退休，担任Nabriva Therapeutics PLC的首席财务官，该公司是一家商业阶段的上市生物制药公司，从事治疗严重感染的创新抗感染药物的商业化和开发。他自2016年5月起担任该职位。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任协同制药公司执行副总裁兼首席财务官。在加入Synergy之前，2009年8月至2015年6月，Sender先生担任Shire plc（“Shire”）的财务高级副总裁，该公司是一家生物制药公司，自被Takeda Pharmaceutical Company Limited收购以来，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生于2004年8月至2009年7月在再生医学公司Tengion, Inc.担任首席财务官。森德先生还曾在上市制药公司默沙东公司担任多个领导职务超过15年。Sender先生获得了波士顿大学的金融学士学位和卡内基梅隆大学的工商管理硕士学位。
- Gary Sender was appointed as a member of Ibio, Inc.'s Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee and as Chair of the Compensation Committee. Mr. Sender currently serves on the board of directors of Schrodinger, Inc., a publicly traded company, and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences Holdings, Inc., a publicly traded pharmaceutical company, and is the chair of their audit committee and is a member of their compensation committee. Mr. Sender serves on the board of Apnimed, a publicly traded biotechnology company, and is the chair of their audit committee. Mr. Sender serves on the board of Hula Therapeutics, a privately held biotechnology company. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi national pharmaceutical and early stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie Mellon University.
- Antonio Gracias
-
Antonio Gracias自2017年9月起担任我们的董事会成员。自2001年9月以来，Gracias先生一直担任Valor Management LLC或Valor（一家私募股权公司）的首席执行官兼首席投资官。Gracias先生自2018年9月起担任Castle Creek Pharmaceuticals董事。他也曾担任Marathon Pharmaceuticals，LLC的董事（2013年11月至2017年5月被PTC Therapeutics收购），以及Solarcity Corporation（2012年至2016年）。Gracias先生自2007年5月起担任特斯拉公司董事会成员，包括2010年9月至2019年4月担任首席独立董事。Gracias先生还担任SpaceX的董事。Gracias先生在乔治敦大学外交学院获得国际金融和经济学学士/硕士顺丰控股S.学位，并在芝加哥大学法学院获得法学博士学位。
Antonio Gracias has been Chief Executive Officer and Chief Investment Officer of Valor Management LLC, or Valor, a private equity firm. Mr. Gracias has served as a director of Castle Creek Pharmaceuticals since September 2018. He also served as a director of Marathon Pharmaceuticals, LLC from November 2013 until its acquisition by PTC Therapeutics in May 2017 and SolarCity Corporation from 2012 to 2016. Mr. Gracias has served on the board of directors of Tesla, Inc., since May 2007 including as Lead Independent Director from September 2010 to April 2019. Mr. Gracias also serves as director of SpaceX. Mr. Gracias received a joint B.S. / M.S.F.S. degree in international finance and economics from Georgetown University School of Foreign Service and a J.D. from the University of Chicago Law School. - Antonio Gracias自2017年9月起担任我们的董事会成员。自2001年9月以来，Gracias先生一直担任Valor Management LLC或Valor（一家私募股权公司）的首席执行官兼首席投资官。Gracias先生自2018年9月起担任Castle Creek Pharmaceuticals董事。他也曾担任Marathon Pharmaceuticals，LLC的董事（2013年11月至2017年5月被PTC Therapeutics收购），以及Solarcity Corporation（2012年至2016年）。Gracias先生自2007年5月起担任特斯拉公司董事会成员，包括2010年9月至2019年4月担任首席独立董事。Gracias先生还担任SpaceX的董事。Gracias先生在乔治敦大学外交学院获得国际金融和经济学学士/硕士顺丰控股S.学位，并在芝加哥大学法学院获得法学博士学位。
- Antonio Gracias has been Chief Executive Officer and Chief Investment Officer of Valor Management LLC, or Valor, a private equity firm. Mr. Gracias has served as a director of Castle Creek Pharmaceuticals since September 2018. He also served as a director of Marathon Pharmaceuticals, LLC from November 2013 until its acquisition by PTC Therapeutics in May 2017 and SolarCity Corporation from 2012 to 2016. Mr. Gracias has served on the board of directors of Tesla, Inc., since May 2007 including as Lead Independent Director from September 2010 to April 2019. Mr. Gracias also serves as director of SpaceX. Mr. Gracias received a joint B.S. / M.S.F.S. degree in international finance and economics from Georgetown University School of Foreign Service and a J.D. from the University of Chicago Law School.
- Juan A. Sabater
-
Juan A.Sabater自2017年以来一直担任我们的董事会成员。Sabater自2010年起在Valor担任多个职位，最近担任总裁。加入Valor之前，Sabater从1998年到2006年担任Goldman Sachs&Co.投资银行部门总经理。他目前也任职于几个私人公司和组织的董事会，包括the Frick Collection and Girls Who Code Inc.。Sabater先生目前担任Augeo Affinity Marketing，Inc.的联合主席，也是休伊特学校（Hewitt School）的董事会成员。他在普林斯顿大学（Princeton University）获得历史学学士学位，在斯坦福大学法学院（Stanford Law School）获得法学博士学位。Sabater先生也曾是美国陆军预备役军官。
Juan A. Sabater has served in various roles at Valor since 2010 most recently as President. Prior to joining Valor, Mr. Sabater was a Managing Director of Goldman Sachs & Co. in their Investment Banking Division, from 1998 to 2006. He also currently serves on the board of several private companies and organizations including The Frick Collection and Girls Who Code Inc. Mr. Sabater currently serves as the Co-Chairman of Augeo Affinity Marketing, Inc., and also sits on the board of trustees of The Hewitt School. He received an A.B. in history from Princeton University and a J.D. from Stanford Law School. Mr. Sabater was also a former officer in the U.S. Army Reserve. - Juan A.Sabater自2017年以来一直担任我们的董事会成员。Sabater自2010年起在Valor担任多个职位，最近担任总裁。加入Valor之前，Sabater从1998年到2006年担任Goldman Sachs&Co.投资银行部门总经理。他目前也任职于几个私人公司和组织的董事会，包括the Frick Collection and Girls Who Code Inc.。Sabater先生目前担任Augeo Affinity Marketing，Inc.的联合主席，也是休伊特学校（Hewitt School）的董事会成员。他在普林斯顿大学（Princeton University）获得历史学学士学位，在斯坦福大学法学院（Stanford Law School）获得法学博士学位。Sabater先生也曾是美国陆军预备役军官。
- Juan A. Sabater has served in various roles at Valor since 2010 most recently as President. Prior to joining Valor, Mr. Sabater was a Managing Director of Goldman Sachs & Co. in their Investment Banking Division, from 1998 to 2006. He also currently serves on the board of several private companies and organizations including The Frick Collection and Girls Who Code Inc. Mr. Sabater currently serves as the Co-Chairman of Augeo Affinity Marketing, Inc., and also sits on the board of trustees of The Hewitt School. He received an A.B. in history from Princeton University and a J.D. from Stanford Law School. Mr. Sabater was also a former officer in the U.S. Army Reserve.
- Linda Szyper
-
Linda Szyper于2018年至2021年担任McCann Health的首席运营官，负责其全球医疗保健网络的整体运营。从2014年到2017年，她担任Circassia Pharmaceuticals的首席商务官，Circassia Pharmaceuticals是一家上市的生物技术和医疗设备公司，总部位于英国，在那里她领导了Biness战略和商业方向。在加入Circassia之前，她是阳狮医疗保健传播集团的首席发展官，该集团曾在Searle Pharmaceuticals和Serono Laboratories担任执行职务。Szyper女士曾是Neos治疗公司的董事会成员，目前是Harmony Biosciences的董事会成员。她获得了Northstern大学的生物医学工程学士学位和DePaul大学的MBA学位。
Linda Szyper has served as Chief Operating Officer of McCann Health from 2018 to 2021, where she was responsible for the overall operations of its global healthcare network. From 2014 to 2017 she was the Chief Commercial Officer at Circassia Pharmaceuticals, a publicly traded biotechnology and medical device company headquartered in the United Kingdom, where she spearheaded biness strategy and commercial direction. Prior to Circassia, she was Chief Development Officer of the Publicis Healthcare Communications Group, which follod executive roles at Searle Pharmaceuticals and Serono Laboratories. Ms. Szyper was a member of the Board of Directors of Neos Therapeutics Inc. and currently sits on the Board of Harmony Biosciences. She earned a BS in Biomedical Engineering from Northstern University and an MBA from DePaul University. - Linda Szyper于2018年至2021年担任McCann Health的首席运营官，负责其全球医疗保健网络的整体运营。从2014年到2017年，她担任Circassia Pharmaceuticals的首席商务官，Circassia Pharmaceuticals是一家上市的生物技术和医疗设备公司，总部位于英国，在那里她领导了Biness战略和商业方向。在加入Circassia之前，她是阳狮医疗保健传播集团的首席发展官，该集团曾在Searle Pharmaceuticals和Serono Laboratories担任执行职务。Szyper女士曾是Neos治疗公司的董事会成员，目前是Harmony Biosciences的董事会成员。她获得了Northstern大学的生物医学工程学士学位和DePaul大学的MBA学位。
- Linda Szyper has served as Chief Operating Officer of McCann Health from 2018 to 2021, where she was responsible for the overall operations of its global healthcare network. From 2014 to 2017 she was the Chief Commercial Officer at Circassia Pharmaceuticals, a publicly traded biotechnology and medical device company headquartered in the United Kingdom, where she spearheaded biness strategy and commercial direction. Prior to Circassia, she was Chief Development Officer of the Publicis Healthcare Communications Group, which follod executive roles at Searle Pharmaceuticals and Serono Laboratories. Ms. Szyper was a member of the Board of Directors of Neos Therapeutics Inc. and currently sits on the Board of Harmony Biosciences. She earned a BS in Biomedical Engineering from Northstern University and an MBA from DePaul University.
- Linda Szyper
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Troy Ignelzi
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kumar Budur
-
Kumar Budur自2023年5月起担任Harmony Biosciences Holdings, Inc.的首席医疗官。此前，Budur博士于2015年8月至2022年2月在上市生物制药公司艾伯维公司担任执行医疗总监。在此之前，Kumar博士在全球研发驱动型制药公司Takeda Pharmaceutical Company Limited担任了六年的职责不断增加的职位。作为国家公认的研发专家，他监督过从晚期发现、早期临床开发到晚期临床开发、上市后研究等项目。他在小分子、生物制剂、药物装置组合的各个发展阶段都有进步的经验。Budur博士参与了多个新药申请（NDA），是其中几个NDA的注册临床试验、提交和批准过程的牵头人。Budur博士在同行评审期刊上发表了50多篇原创研究论文，编辑了四本书，并主持了国家和国际研讨会和研讨会。Budur博士在英国剑桥大学和克利夫兰诊所接受培训，并完成了精神病学和神经生理学和睡眠医学研究金的实习。获精神病学和睡眠医学Board认证，获凯斯西储大学临床研究硕士学位。
Kumar Budur has served as Harmony Biosciences Holdings, Inc.'s Chief Medical Officer since May 2023. Previously, Dr. Budur was the Executive Medical Director at AbbVie Inc., a public biopharmaceuticals company, from August 2015 to February 2022.Prior to this, Dr. Kumar held positions of increasing responsibilities for six years at Takeda Pharmaceutical Company Limited, a global, research and development driven pharmaceutical company. A nationally recognized expert in Research and Development, he has overseen programs ranging from late discovery, early clinical development to late clinical development, and post marketing studies. He has experience in progressing small molecules, biologics, drug device combination through various stages of Development. Dr. Budur was involved with multiple New Drug Applications (NDAs) and was the lead for the registration clinical trials, submission, and approval process of several of these NDAs. Dr. Budur has published over 50 original research papers in peer reviewed journals, edited four books, and chaired National and International seminars and symposiums. Dr. Budur was trained at Cambridge University in the UK, and Cleveland Clinic and completed his Residency in Psychiatry and Fellowships in Neurophysiology and Sleep Medicine. He is Board Certified in Psychiatry and Sleep Medicine and received a master's degree in clinical research from Case Western Reserve University. - Kumar Budur自2023年5月起担任Harmony Biosciences Holdings, Inc.的首席医疗官。此前，Budur博士于2015年8月至2022年2月在上市生物制药公司艾伯维公司担任执行医疗总监。在此之前，Kumar博士在全球研发驱动型制药公司Takeda Pharmaceutical Company Limited担任了六年的职责不断增加的职位。作为国家公认的研发专家，他监督过从晚期发现、早期临床开发到晚期临床开发、上市后研究等项目。他在小分子、生物制剂、药物装置组合的各个发展阶段都有进步的经验。Budur博士参与了多个新药申请（NDA），是其中几个NDA的注册临床试验、提交和批准过程的牵头人。Budur博士在同行评审期刊上发表了50多篇原创研究论文，编辑了四本书，并主持了国家和国际研讨会和研讨会。Budur博士在英国剑桥大学和克利夫兰诊所接受培训，并完成了精神病学和神经生理学和睡眠医学研究金的实习。获精神病学和睡眠医学Board认证，获凯斯西储大学临床研究硕士学位。
- Kumar Budur has served as Harmony Biosciences Holdings, Inc.'s Chief Medical Officer since May 2023. Previously, Dr. Budur was the Executive Medical Director at AbbVie Inc., a public biopharmaceuticals company, from August 2015 to February 2022.Prior to this, Dr. Kumar held positions of increasing responsibilities for six years at Takeda Pharmaceutical Company Limited, a global, research and development driven pharmaceutical company. A nationally recognized expert in Research and Development, he has overseen programs ranging from late discovery, early clinical development to late clinical development, and post marketing studies. He has experience in progressing small molecules, biologics, drug device combination through various stages of Development. Dr. Budur was involved with multiple New Drug Applications (NDAs) and was the lead for the registration clinical trials, submission, and approval process of several of these NDAs. Dr. Budur has published over 50 original research papers in peer reviewed journals, edited four books, and chaired National and International seminars and symposiums. Dr. Budur was trained at Cambridge University in the UK, and Cleveland Clinic and completed his Residency in Psychiatry and Fellowships in Neurophysiology and Sleep Medicine. He is Board Certified in Psychiatry and Sleep Medicine and received a master's degree in clinical research from Case Western Reserve University.
- Ron Philip
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- R. Mark Graf
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jeffrey M. Dayno
-
Jeffrey M. Dayno是公司首席医疗官，自2014年7月起担任该职位。Dayno于2014年5月到2014年6月担任公司顾问。加入Egalet之前，Dayno曾担任ViroPharma Inc.（一家制药公司，2014年初被Shire Pharmaceuticals Group plc收购）全球医疗事务副总裁，2011年8月到2014年4月担任多个高级研发和领导小组以及投资组合管理小组成员。加入ViroPharma之前，Dayno曾于2010年5月到2011年7月担任Labopharm, Inc.（加拿大一家生物技术公司）首席医疗官，监管Labopharm所有的研发活动，在滥用-摄止物阿片样物质产品开发领域获得了丰富的经验。加入Labopharm之前，Dayno 曾于2005年12月到2010年4月担任Cephalon Inc.医疗服务副总裁，监管Cephalon的阶段3B/4临床开发项目。Dayno在Merck & Co., Inc.开始自己的制药领域职业生涯，在该公司任职7年，在医疗和科学事务领域担任过多个职位。Dayno是委员会认证的神经学专家，在Henry Ford Hospital完成了Henry Ford Hospital（为中风和偏头痛/头痛疾患提供NIH Program Grant）专科训练。他在学术/临床医学领域花费了10年时间，曾担任中风和偏头痛领域多个临床试验的主要研究员。2014年5月Dayno被邀请担任Temple University School of Medicine客座董事。
Jeffrey M. Dayno is Chief Medical Officer, a position he has held since July 2014. From May 2014 to June 2014 Dr. Dayno served as consultant. Prior to joining Egalet, Dr. Dayno served as Vice President, Global Medical Affairs, at ViroPharma Inc., a pharmaceutical company acquired by Shire Pharmaceuticals Group plc in early 2014 where he was a member of several senior research and development leadership teams and the portfolio management team, from August 2011 to April 2014. Before joining Labopharm, Dr. Dayno served as the Vice President, Medical Services, at Cephalon Inc. from December 2005 to April 2010 where he directed Cephalon's Phase 3B/4 clinical development programs. Dr. Dayno started his career in the pharmaceutical industry at Merck & Co., Inc. where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division. Dr. Dayno earned his medical degree from Temple University School of Medicine, completed a fellowship in stroke and cerebrovascular disorders in the Department of Neurology at Henry Ford Hospital, a National Institutes of Health NIH Clinical Research Center for stroke and headache, and was board certified in neurology. He spent ten years in academic/clinical medicine, during which time he served as the principal investigator on numerous clinical trials in the areas of stroke and migraine. Dr. Dayno has served on the Board of Visitors of Temple University School of Medicine since May 2014. - Jeffrey M. Dayno是公司首席医疗官，自2014年7月起担任该职位。Dayno于2014年5月到2014年6月担任公司顾问。加入Egalet之前，Dayno曾担任ViroPharma Inc.（一家制药公司，2014年初被Shire Pharmaceuticals Group plc收购）全球医疗事务副总裁，2011年8月到2014年4月担任多个高级研发和领导小组以及投资组合管理小组成员。加入ViroPharma之前，Dayno曾于2010年5月到2011年7月担任Labopharm, Inc.（加拿大一家生物技术公司）首席医疗官，监管Labopharm所有的研发活动，在滥用-摄止物阿片样物质产品开发领域获得了丰富的经验。加入Labopharm之前，Dayno 曾于2005年12月到2010年4月担任Cephalon Inc.医疗服务副总裁，监管Cephalon的阶段3B/4临床开发项目。Dayno在Merck & Co., Inc.开始自己的制药领域职业生涯，在该公司任职7年，在医疗和科学事务领域担任过多个职位。Dayno是委员会认证的神经学专家，在Henry Ford Hospital完成了Henry Ford Hospital（为中风和偏头痛/头痛疾患提供NIH Program Grant）专科训练。他在学术/临床医学领域花费了10年时间，曾担任中风和偏头痛领域多个临床试验的主要研究员。2014年5月Dayno被邀请担任Temple University School of Medicine客座董事。
- Jeffrey M. Dayno is Chief Medical Officer, a position he has held since July 2014. From May 2014 to June 2014 Dr. Dayno served as consultant. Prior to joining Egalet, Dr. Dayno served as Vice President, Global Medical Affairs, at ViroPharma Inc., a pharmaceutical company acquired by Shire Pharmaceuticals Group plc in early 2014 where he was a member of several senior research and development leadership teams and the portfolio management team, from August 2011 to April 2014. Before joining Labopharm, Dr. Dayno served as the Vice President, Medical Services, at Cephalon Inc. from December 2005 to April 2010 where he directed Cephalon's Phase 3B/4 clinical development programs. Dr. Dayno started his career in the pharmaceutical industry at Merck & Co., Inc. where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division. Dr. Dayno earned his medical degree from Temple University School of Medicine, completed a fellowship in stroke and cerebrovascular disorders in the Department of Neurology at Henry Ford Hospital, a National Institutes of Health NIH Clinical Research Center for stroke and headache, and was board certified in neurology. He spent ten years in academic/clinical medicine, during which time he served as the principal investigator on numerous clinical trials in the areas of stroke and migraine. Dr. Dayno has served on the Board of Visitors of Temple University School of Medicine since May 2014.
- Andreas Wicki
-
Andreas Wicki，在2006年12月公司成立时担任我们的董事。他是一名生命科学企业家和投资者，拥有20多年的制药和生物技术产业经验。他自2001年起是HBM Partners AG和HBM Healthcare Investments AG（前身是HBM BioVentures AG）的首席执行官。从1998年到2001年他是MDS股份有限公司European Analytical Operations的高级副总裁。从1990年到1998年他是ANAWA Laboratorien AG和Clinserve AG（两个签订合同的生命科学研究公司）共同拥有者和首席执行官。从2007年到2011年他是PharmaSwiss SA董事会的成员。先前，他在几家私人控股公司担任董事职位，并且公司在国际交易所上市。他拥有瑞士伯尔尼大学（the University of Bern, Switzerland）化学和生物化学硕士和博士学位。他目前在Buchler GmbH, HBM Healthcare Investments （Cayman） Ltd., HBM Partners Ltd和 HBM BioCapital Ltd董事会工作。
Andreas Wicki is a life sciences entrepreneur and investor with over 16 years of experience in the pharmaceutical and biotechnology industries. Dr. Wicki has been chief executive officer of HBM Partners AG and HBM BioVentures AG since 2001. From 1998 to 2001 Dr. Wicki was the senior vice president of the European Analytical Operations at MDS Inc. From 1990 to 1998 he was co-owner and chief executive officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the board of directors of Buchler GmbH, HBM BioPharma India Ltd., HBM BioVentures Cayman Ltd., HBM Partners Ltd. and PharmaSwiss SA. - Andreas Wicki，在2006年12月公司成立时担任我们的董事。他是一名生命科学企业家和投资者，拥有20多年的制药和生物技术产业经验。他自2001年起是HBM Partners AG和HBM Healthcare Investments AG（前身是HBM BioVentures AG）的首席执行官。从1998年到2001年他是MDS股份有限公司European Analytical Operations的高级副总裁。从1990年到1998年他是ANAWA Laboratorien AG和Clinserve AG（两个签订合同的生命科学研究公司）共同拥有者和首席执行官。从2007年到2011年他是PharmaSwiss SA董事会的成员。先前，他在几家私人控股公司担任董事职位，并且公司在国际交易所上市。他拥有瑞士伯尔尼大学（the University of Bern, Switzerland）化学和生物化学硕士和博士学位。他目前在Buchler GmbH, HBM Healthcare Investments （Cayman） Ltd., HBM Partners Ltd和 HBM BioCapital Ltd董事会工作。
- Andreas Wicki is a life sciences entrepreneur and investor with over 16 years of experience in the pharmaceutical and biotechnology industries. Dr. Wicki has been chief executive officer of HBM Partners AG and HBM BioVentures AG since 2001. From 1998 to 2001 Dr. Wicki was the senior vice president of the European Analytical Operations at MDS Inc. From 1990 to 1998 he was co-owner and chief executive officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the board of directors of Buchler GmbH, HBM BioPharma India Ltd., HBM BioVentures Cayman Ltd., HBM Partners Ltd. and PharmaSwiss SA.
- Jeffrey S. Aronin
-
Jeffrey S. Aronin，他现任Paragon制药公司董事长兼首席执行官，该公司是一家全球发展和生物制药投资公司。同时，他还是处方制药公司Marathon制药公司董事长兼首席执行官。2000年至2009年他曾任奥维森制药公司总裁兼首席执行官。奥维森制药公司是由他本人于2000年创立的一家生物制药公司，2009年被丹麦灵北制药公司收购。2009年丹麦灵北收购整合奥维森制药公司期间，他曾任丹麦灵北总裁兼首席执行官。他曾任MedCare技术公司董事长兼首席执行官，该公司为一家上市医疗保健公司。
Jeffrey S. Aronin,Founder, chairman and chief executive officer of Paragon Biosciences, LLC, an affiliated global life science innovation and investment firm.Established and is chairman of several of Paragon's portfolio companies - Harmony Biosciences (Nasdaq – HRMY), Castle Creek Biosciences, Emalex Biosciences, Evozyne and CIRC Biosciences since 2017.Previously served as CEO of several global biopharmaceutical companies focused on therapies for people with high unmet medical needs. - Jeffrey S. Aronin，他现任Paragon制药公司董事长兼首席执行官，该公司是一家全球发展和生物制药投资公司。同时，他还是处方制药公司Marathon制药公司董事长兼首席执行官。2000年至2009年他曾任奥维森制药公司总裁兼首席执行官。奥维森制药公司是由他本人于2000年创立的一家生物制药公司，2009年被丹麦灵北制药公司收购。2009年丹麦灵北收购整合奥维森制药公司期间，他曾任丹麦灵北总裁兼首席执行官。他曾任MedCare技术公司董事长兼首席执行官，该公司为一家上市医疗保健公司。
- Jeffrey S. Aronin,Founder, chairman and chief executive officer of Paragon Biosciences, LLC, an affiliated global life science innovation and investment firm.Established and is chairman of several of Paragon's portfolio companies - Harmony Biosciences (Nasdaq – HRMY), Castle Creek Biosciences, Emalex Biosciences, Evozyne and CIRC Biosciences since 2017.Previously served as CEO of several global biopharmaceutical companies focused on therapies for people with high unmet medical needs.
高管简历
中英对照 | 中文 | 英文- Sandip Kapadia
Sandip Kapadia先生自2020年4月起担任Molecular Partners AG董事。Kapadia先生目前担任Harmony Bioscience的首席财务官。卡帕迪亚先生在欧洲和美国的生命科学公司建立和领导财务和管理团队方面拥有超过20年的经验。在加入Harmony Bioscience之前，Kapadia先生在2016年至2021年3月底期间担任Intercept Pharmaceuticals的首席财务官和财务主管。在2016年加入Intercept之前，Kapadia先生在诺华和诺华在美国、瑞士、荷兰的分公司担任了19年的财务领导职务，以及英国，包括诺华仿制药部门北美首席财务官桑多兹。Kapadia先生自2020年1月起担任Passation Bio董事，自2020年12月起担任Vectiv Bio Holding AG董事，之前担任Therachon AG董事。Kapadia先生获得了蒙特克莱尔州立大学工商管理和会计学士学位，来自罗格斯大学管理学院的工商管理硕士学位，是一名注册会计师。
Sandip Kapadia has served as a director since April 2020. Mr. Kapadia has served as the Chief Financial Officer (CFO) for Harmony Biosciences since March 2021. Previoly Mr. Kapadia was CFO for Intercept Pharmaceuticals. Before Intercept, Mr. Kapadia served in vario leadership capacities within finance for more than 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the . Mr. Kapadia received a B.S. in Accounting from Montclair State University and an M.B.A. from Rutgers University, and is also a Certified Public Accountant. Mr. Kapadia currently serves on the board of directors of Passage Bio, Inc., Alentis Therapeutics AG, and previoly on the board of directors of VectivBio Holding AG and Therachon AG.- Sandip Kapadia先生自2020年4月起担任Molecular Partners AG董事。Kapadia先生目前担任Harmony Bioscience的首席财务官。卡帕迪亚先生在欧洲和美国的生命科学公司建立和领导财务和管理团队方面拥有超过20年的经验。在加入Harmony Bioscience之前，Kapadia先生在2016年至2021年3月底期间担任Intercept Pharmaceuticals的首席财务官和财务主管。在2016年加入Intercept之前，Kapadia先生在诺华和诺华在美国、瑞士、荷兰的分公司担任了19年的财务领导职务，以及英国，包括诺华仿制药部门北美首席财务官桑多兹。Kapadia先生自2020年1月起担任Passation Bio董事，自2020年12月起担任Vectiv Bio Holding AG董事，之前担任Therachon AG董事。Kapadia先生获得了蒙特克莱尔州立大学工商管理和会计学士学位，来自罗格斯大学管理学院的工商管理硕士学位，是一名注册会计师。
- Sandip Kapadia has served as a director since April 2020. Mr. Kapadia has served as the Chief Financial Officer (CFO) for Harmony Biosciences since March 2021. Previoly Mr. Kapadia was CFO for Intercept Pharmaceuticals. Before Intercept, Mr. Kapadia served in vario leadership capacities within finance for more than 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the . Mr. Kapadia received a B.S. in Accounting from Montclair State University and an M.B.A. from Rutgers University, and is also a Certified Public Accountant. Mr. Kapadia currently serves on the board of directors of Passage Bio, Inc., Alentis Therapeutics AG, and previoly on the board of directors of VectivBio Holding AG and Therachon AG.
- Andrew Serafin
Andrew Serafin自2018年12月起担任我们的首席商务官。Serafin先生曾于2017年9月至2018年12月担任我们的业务发展和公司战略高级副总裁。此前，塞拉芬曾于2015年8月至2017年5月担任私人发展阶段生物制药公司Marathon Pharmaceuticals，LLC业务发展Vice President。他还于2015年4月至2015年8月担任私人制药公司Altathera Pharmaceuticals，LLC的业务发展and General Counsel Vice President，并于2006年7月至2015年3月担任Lundbeck Inc.（或Lundbeck）的交易整合Vice President兼副总法律顾问。任职公司期间，他也曾担任Lundbeck公司的代理总法律顾问6个月。他在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得金融学学士学位，在洛约拉大学芝加哥法学院（Loyola University Chicago School of Law）获得法学博士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
Andrew Serafin has served as Harmony Biosciences Holdings, Inc.'s Chief Strategy Officer since January 2021. Previously, Mr. Serafin served as Harmony Biosciences Holdings, Inc.'s Chief Business Officer from December 2018 to January 2021 and as Harmony Biosciences Holdings, Inc.'s Senior Vice President of Business Development and Corporate Strategy from September 2017 to December 2018. Previously, Mr. Serafin served as the Vice President of Business Development at Marathon Pharmaceuticals, LLC, a private development stage biopharmaceutical company, from August 2015 to May 2017. He also served as the Vice President of Business Development and General Counsel of AltaThera Pharmaceuticals, LLC, a private pharmaceutical company, from April 2015 to August 2015, and the Vice President of Deal Integration and Associate General Counsel of Lundbeck Inc., or Lundbeck, from July 2006 to March 2015. He also served as acting General Counsel of Lundbeck for six months during his time with the company. Mr. Serafin has over 25 years of experience in mergers and acquisitions and corporate legal counseling in the pharmaceutical, healthcare and technology sectors. He received a B.S. in finance from University of Illinois at Urbana Champaign, a J.D. from Loyola University Chicago School of Law and an M.B.A. from Northwestern University Kellogg School of Management.- Andrew Serafin自2018年12月起担任我们的首席商务官。Serafin先生曾于2017年9月至2018年12月担任我们的业务发展和公司战略高级副总裁。此前，塞拉芬曾于2015年8月至2017年5月担任私人发展阶段生物制药公司Marathon Pharmaceuticals，LLC业务发展Vice President。他还于2015年4月至2015年8月担任私人制药公司Altathera Pharmaceuticals，LLC的业务发展and General Counsel Vice President，并于2006年7月至2015年3月担任Lundbeck Inc.（或Lundbeck）的交易整合Vice President兼副总法律顾问。任职公司期间，他也曾担任Lundbeck公司的代理总法律顾问6个月。他在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得金融学学士学位，在洛约拉大学芝加哥法学院（Loyola University Chicago School of Law）获得法学博士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
- Andrew Serafin has served as Harmony Biosciences Holdings, Inc.'s Chief Strategy Officer since January 2021. Previously, Mr. Serafin served as Harmony Biosciences Holdings, Inc.'s Chief Business Officer from December 2018 to January 2021 and as Harmony Biosciences Holdings, Inc.'s Senior Vice President of Business Development and Corporate Strategy from September 2017 to December 2018. Previously, Mr. Serafin served as the Vice President of Business Development at Marathon Pharmaceuticals, LLC, a private development stage biopharmaceutical company, from August 2015 to May 2017. He also served as the Vice President of Business Development and General Counsel of AltaThera Pharmaceuticals, LLC, a private pharmaceutical company, from April 2015 to August 2015, and the Vice President of Deal Integration and Associate General Counsel of Lundbeck Inc., or Lundbeck, from July 2006 to March 2015. He also served as acting General Counsel of Lundbeck for six months during his time with the company. Mr. Serafin has over 25 years of experience in mergers and acquisitions and corporate legal counseling in the pharmaceutical, healthcare and technology sectors. He received a B.S. in finance from University of Illinois at Urbana Champaign, a J.D. from Loyola University Chicago School of Law and an M.B.A. from Northwestern University Kellogg School of Management.
- Peter Anastasiou
Peter Anastasiou自2026年4月起担任公司首席运营官。他曾于2022年1月至2025年10月担任下一代综合基因治疗公司Capsida Biotherapeutics的首席执行官和董事会成员。在加入Capsida之前，从2009年11月到2021年12月，Anastasiou先生在Lundbeck担任过各种职务，Lundbeck是一家在哥本哈根证券交易所上市的制药公司，最近担任执行副总裁兼北美总裁，在此之前担任美国首席商务官和副总裁兼精神病学总经理。此外，他曾于2023年11月至2026年4月担任公司董事会成员，并于2016年1月至2021年12月担任Lundbeck美国法人机构董事会成员。Anastasiou先生目前在医疗保健女企业家协会全球咨询委员会任职，此前曾在多个私营组织的董事会任职，包括药物研究和制造商协会（PhRMA）、Kids Above All和Bear Necessities儿科癌症基金会。Anastasiou先生获得了阿尔比恩学院的经济和管理学士学位和印第安纳大学凯利商学院的工商管理硕士学位。
Peter Anastasiou has served as the Company's Chief Operating Officer since April 2026. He served as Chief Executive Officer and as a member of the board of directors of Capsida Biotherapeutics, a next generation integrated gene therapy company, from January 2022 to October 2025. Prior to Capsida, from November 2009 to December 2021, Mr. Anastasiou served in various roles at Lundbeck, a pharmaceutical company publicly traded on the Copenhagen Stock Exchange, including most recently as Executive Vice President and President of North America, and prior to that as Chief Commercial Officer for the U.S. and Vice President and General Manager for Psychiatry. In addition, he previously served as a member of the Company's Board from November 2023 to April 2026, and as a member of the board of directors of Lundbeck's U.S. legal entities from January 2016 to December 2021. Mr. Anastasiou currently serves on the Global Advisory Board of the Healthcare Businesswomen's Association and has previously served on the boards of several private organizations, including the Pharmaceutical Research and Manufacturers Association (PhRMA), Kids Above All and Bear Necessities Pediatric Cancer Foundation. Mr. Anastasiou received a B.A. in Economics and Management from Albion College and an M.B.A. from the Kelley School of Business, Indiana University.- Peter Anastasiou自2026年4月起担任公司首席运营官。他曾于2022年1月至2025年10月担任下一代综合基因治疗公司Capsida Biotherapeutics的首席执行官和董事会成员。在加入Capsida之前，从2009年11月到2021年12月，Anastasiou先生在Lundbeck担任过各种职务，Lundbeck是一家在哥本哈根证券交易所上市的制药公司，最近担任执行副总裁兼北美总裁，在此之前担任美国首席商务官和副总裁兼精神病学总经理。此外，他曾于2023年11月至2026年4月担任公司董事会成员，并于2016年1月至2021年12月担任Lundbeck美国法人机构董事会成员。Anastasiou先生目前在医疗保健女企业家协会全球咨询委员会任职，此前曾在多个私营组织的董事会任职，包括药物研究和制造商协会（PhRMA）、Kids Above All和Bear Necessities儿科癌症基金会。Anastasiou先生获得了阿尔比恩学院的经济和管理学士学位和印第安纳大学凯利商学院的工商管理硕士学位。
- Peter Anastasiou has served as the Company's Chief Operating Officer since April 2026. He served as Chief Executive Officer and as a member of the board of directors of Capsida Biotherapeutics, a next generation integrated gene therapy company, from January 2022 to October 2025. Prior to Capsida, from November 2009 to December 2021, Mr. Anastasiou served in various roles at Lundbeck, a pharmaceutical company publicly traded on the Copenhagen Stock Exchange, including most recently as Executive Vice President and President of North America, and prior to that as Chief Commercial Officer for the U.S. and Vice President and General Manager for Psychiatry. In addition, he previously served as a member of the Company's Board from November 2023 to April 2026, and as a member of the board of directors of Lundbeck's U.S. legal entities from January 2016 to December 2021. Mr. Anastasiou currently serves on the Global Advisory Board of the Healthcare Businesswomen's Association and has previously served on the boards of several private organizations, including the Pharmaceutical Research and Manufacturers Association (PhRMA), Kids Above All and Bear Necessities Pediatric Cancer Foundation. Mr. Anastasiou received a B.A. in Economics and Management from Albion College and an M.B.A. from the Kelley School of Business, Indiana University.
- Adam Zaeske
Adam Zaeske自2025年3月起担任Harmony Biosciences Holdings, Inc.的首席商务官。在加入Harmony之前，Zaeske先生自2004年以来在武田制药担任过各种职务，最近一次是在2022年4月至2025年3月期间担任高级副总裁兼中南欧和东欧负责人。在加入武田制药之前，Zaeske先生于2002年至2004年担任百特国际全球市场经理。Zaeske先生在制药行业拥有超过25年的全球领导地位，在美国和欧洲建立团队并改造组织。Zaeske先生获得了密歇根大学的学士学位和哈佛商学院的工商管理硕士学位。
Adam Zaeske has served as Harmony Biosciences Holdings, Inc.'s Chief Commercial Officer since March 2025. Prior to joining Harmony, Mr. Zaeske served in various roles for Takeda Pharmaceuticals since 2004, most recently as Senior Vice President and Head of Central South and East Europe from April 2022 to March 2025. Prior to joining Takeda Pharmaceuticals, Mr. Zaeske served as Global Marketing Manager for Baxter International from 2002 to 2004. Mr. Zaeske has over 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the United States and Europe. Mr. Zaeske received a B.B.A. from the University of Michigan and an M.B.A. from Harvard Business School.- Adam Zaeske自2025年3月起担任Harmony Biosciences Holdings, Inc.的首席商务官。在加入Harmony之前，Zaeske先生自2004年以来在武田制药担任过各种职务，最近一次是在2022年4月至2025年3月期间担任高级副总裁兼中南欧和东欧负责人。在加入武田制药之前，Zaeske先生于2002年至2004年担任百特国际全球市场经理。Zaeske先生在制药行业拥有超过25年的全球领导地位，在美国和欧洲建立团队并改造组织。Zaeske先生获得了密歇根大学的学士学位和哈佛商学院的工商管理硕士学位。
- Adam Zaeske has served as Harmony Biosciences Holdings, Inc.'s Chief Commercial Officer since March 2025. Prior to joining Harmony, Mr. Zaeske served in various roles for Takeda Pharmaceuticals since 2004, most recently as Senior Vice President and Head of Central South and East Europe from April 2022 to March 2025. Prior to joining Takeda Pharmaceuticals, Mr. Zaeske served as Global Marketing Manager for Baxter International from 2002 to 2004. Mr. Zaeske has over 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the United States and Europe. Mr. Zaeske received a B.B.A. from the University of Michigan and an M.B.A. from Harvard Business School.
- Kumar Budur
Kumar Budur自2023年5月起担任Harmony Biosciences Holdings, Inc.的首席医疗官。此前，Budur博士于2015年8月至2022年2月在上市生物制药公司艾伯维公司担任执行医疗总监。在此之前，Kumar博士在全球研发驱动型制药公司Takeda Pharmaceutical Company Limited担任了六年的职责不断增加的职位。作为国家公认的研发专家，他监督过从晚期发现、早期临床开发到晚期临床开发、上市后研究等项目。他在小分子、生物制剂、药物装置组合的各个发展阶段都有进步的经验。Budur博士参与了多个新药申请（NDA），是其中几个NDA的注册临床试验、提交和批准过程的牵头人。Budur博士在同行评审期刊上发表了50多篇原创研究论文，编辑了四本书，并主持了国家和国际研讨会和研讨会。Budur博士在英国剑桥大学和克利夫兰诊所接受培训，并完成了精神病学和神经生理学和睡眠医学研究金的实习。获精神病学和睡眠医学Board认证，获凯斯西储大学临床研究硕士学位。
Kumar Budur has served as Harmony Biosciences Holdings, Inc.'s Chief Medical Officer since May 2023. Previously, Dr. Budur was the Executive Medical Director at AbbVie Inc., a public biopharmaceuticals company, from August 2015 to February 2022.Prior to this, Dr. Kumar held positions of increasing responsibilities for six years at Takeda Pharmaceutical Company Limited, a global, research and development driven pharmaceutical company. A nationally recognized expert in Research and Development, he has overseen programs ranging from late discovery, early clinical development to late clinical development, and post marketing studies. He has experience in progressing small molecules, biologics, drug device combination through various stages of Development. Dr. Budur was involved with multiple New Drug Applications (NDAs) and was the lead for the registration clinical trials, submission, and approval process of several of these NDAs. Dr. Budur has published over 50 original research papers in peer reviewed journals, edited four books, and chaired National and International seminars and symposiums. Dr. Budur was trained at Cambridge University in the UK, and Cleveland Clinic and completed his Residency in Psychiatry and Fellowships in Neurophysiology and Sleep Medicine. He is Board Certified in Psychiatry and Sleep Medicine and received a master's degree in clinical research from Case Western Reserve University.- Kumar Budur自2023年5月起担任Harmony Biosciences Holdings, Inc.的首席医疗官。此前，Budur博士于2015年8月至2022年2月在上市生物制药公司艾伯维公司担任执行医疗总监。在此之前，Kumar博士在全球研发驱动型制药公司Takeda Pharmaceutical Company Limited担任了六年的职责不断增加的职位。作为国家公认的研发专家，他监督过从晚期发现、早期临床开发到晚期临床开发、上市后研究等项目。他在小分子、生物制剂、药物装置组合的各个发展阶段都有进步的经验。Budur博士参与了多个新药申请（NDA），是其中几个NDA的注册临床试验、提交和批准过程的牵头人。Budur博士在同行评审期刊上发表了50多篇原创研究论文，编辑了四本书，并主持了国家和国际研讨会和研讨会。Budur博士在英国剑桥大学和克利夫兰诊所接受培训，并完成了精神病学和神经生理学和睡眠医学研究金的实习。获精神病学和睡眠医学Board认证，获凯斯西储大学临床研究硕士学位。
- Kumar Budur has served as Harmony Biosciences Holdings, Inc.'s Chief Medical Officer since May 2023. Previously, Dr. Budur was the Executive Medical Director at AbbVie Inc., a public biopharmaceuticals company, from August 2015 to February 2022.Prior to this, Dr. Kumar held positions of increasing responsibilities for six years at Takeda Pharmaceutical Company Limited, a global, research and development driven pharmaceutical company. A nationally recognized expert in Research and Development, he has overseen programs ranging from late discovery, early clinical development to late clinical development, and post marketing studies. He has experience in progressing small molecules, biologics, drug device combination through various stages of Development. Dr. Budur was involved with multiple New Drug Applications (NDAs) and was the lead for the registration clinical trials, submission, and approval process of several of these NDAs. Dr. Budur has published over 50 original research papers in peer reviewed journals, edited four books, and chaired National and International seminars and symposiums. Dr. Budur was trained at Cambridge University in the UK, and Cleveland Clinic and completed his Residency in Psychiatry and Fellowships in Neurophysiology and Sleep Medicine. He is Board Certified in Psychiatry and Sleep Medicine and received a master's degree in clinical research from Case Western Reserve University.
- Jeffrey M. Dayno
Jeffrey M. Dayno是公司首席医疗官，自2014年7月起担任该职位。Dayno于2014年5月到2014年6月担任公司顾问。加入Egalet之前，Dayno曾担任ViroPharma Inc.（一家制药公司，2014年初被Shire Pharmaceuticals Group plc收购）全球医疗事务副总裁，2011年8月到2014年4月担任多个高级研发和领导小组以及投资组合管理小组成员。加入ViroPharma之前，Dayno曾于2010年5月到2011年7月担任Labopharm, Inc.（加拿大一家生物技术公司）首席医疗官，监管Labopharm所有的研发活动，在滥用-摄止物阿片样物质产品开发领域获得了丰富的经验。加入Labopharm之前，Dayno 曾于2005年12月到2010年4月担任Cephalon Inc.医疗服务副总裁，监管Cephalon的阶段3B/4临床开发项目。Dayno在Merck & Co., Inc.开始自己的制药领域职业生涯，在该公司任职7年，在医疗和科学事务领域担任过多个职位。Dayno是委员会认证的神经学专家，在Henry Ford Hospital完成了Henry Ford Hospital（为中风和偏头痛/头痛疾患提供NIH Program Grant）专科训练。他在学术/临床医学领域花费了10年时间，曾担任中风和偏头痛领域多个临床试验的主要研究员。2014年5月Dayno被邀请担任Temple University School of Medicine客座董事。
Jeffrey M. Dayno is Chief Medical Officer, a position he has held since July 2014. From May 2014 to June 2014 Dr. Dayno served as consultant. Prior to joining Egalet, Dr. Dayno served as Vice President, Global Medical Affairs, at ViroPharma Inc., a pharmaceutical company acquired by Shire Pharmaceuticals Group plc in early 2014 where he was a member of several senior research and development leadership teams and the portfolio management team, from August 2011 to April 2014. Before joining Labopharm, Dr. Dayno served as the Vice President, Medical Services, at Cephalon Inc. from December 2005 to April 2010 where he directed Cephalon's Phase 3B/4 clinical development programs. Dr. Dayno started his career in the pharmaceutical industry at Merck & Co., Inc. where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division. Dr. Dayno earned his medical degree from Temple University School of Medicine, completed a fellowship in stroke and cerebrovascular disorders in the Department of Neurology at Henry Ford Hospital, a National Institutes of Health NIH Clinical Research Center for stroke and headache, and was board certified in neurology. He spent ten years in academic/clinical medicine, during which time he served as the principal investigator on numerous clinical trials in the areas of stroke and migraine. Dr. Dayno has served on the Board of Visitors of Temple University School of Medicine since May 2014.- Jeffrey M. Dayno是公司首席医疗官，自2014年7月起担任该职位。Dayno于2014年5月到2014年6月担任公司顾问。加入Egalet之前，Dayno曾担任ViroPharma Inc.（一家制药公司，2014年初被Shire Pharmaceuticals Group plc收购）全球医疗事务副总裁，2011年8月到2014年4月担任多个高级研发和领导小组以及投资组合管理小组成员。加入ViroPharma之前，Dayno曾于2010年5月到2011年7月担任Labopharm, Inc.（加拿大一家生物技术公司）首席医疗官，监管Labopharm所有的研发活动，在滥用-摄止物阿片样物质产品开发领域获得了丰富的经验。加入Labopharm之前，Dayno 曾于2005年12月到2010年4月担任Cephalon Inc.医疗服务副总裁，监管Cephalon的阶段3B/4临床开发项目。Dayno在Merck & Co., Inc.开始自己的制药领域职业生涯，在该公司任职7年，在医疗和科学事务领域担任过多个职位。Dayno是委员会认证的神经学专家，在Henry Ford Hospital完成了Henry Ford Hospital（为中风和偏头痛/头痛疾患提供NIH Program Grant）专科训练。他在学术/临床医学领域花费了10年时间，曾担任中风和偏头痛领域多个临床试验的主要研究员。2014年5月Dayno被邀请担任Temple University School of Medicine客座董事。
- Jeffrey M. Dayno is Chief Medical Officer, a position he has held since July 2014. From May 2014 to June 2014 Dr. Dayno served as consultant. Prior to joining Egalet, Dr. Dayno served as Vice President, Global Medical Affairs, at ViroPharma Inc., a pharmaceutical company acquired by Shire Pharmaceuticals Group plc in early 2014 where he was a member of several senior research and development leadership teams and the portfolio management team, from August 2011 to April 2014. Before joining Labopharm, Dr. Dayno served as the Vice President, Medical Services, at Cephalon Inc. from December 2005 to April 2010 where he directed Cephalon's Phase 3B/4 clinical development programs. Dr. Dayno started his career in the pharmaceutical industry at Merck & Co., Inc. where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division. Dr. Dayno earned his medical degree from Temple University School of Medicine, completed a fellowship in stroke and cerebrovascular disorders in the Department of Neurology at Henry Ford Hospital, a National Institutes of Health NIH Clinical Research Center for stroke and headache, and was board certified in neurology. He spent ten years in academic/clinical medicine, during which time he served as the principal investigator on numerous clinical trials in the areas of stroke and migraine. Dr. Dayno has served on the Board of Visitors of Temple University School of Medicine since May 2014.